(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Biohaven's earnings in 2025 is -$780,110,000.On average, 20 Wall Street analysts forecast BHVN's earnings for 2025 to be -$747,168,026, with the lowest BHVN earnings forecast at -$905,633,193, and the highest BHVN earnings forecast at -$620,205,353. On average, 20 Wall Street analysts forecast BHVN's earnings for 2026 to be -$381,343,196, with the lowest BHVN earnings forecast at -$816,418,468, and the highest BHVN earnings forecast at -$221,184,346.
In 2027, BHVN is forecast to generate -$298,151,630 in earnings, with the lowest earnings forecast at -$720,979,461 and the highest earnings forecast at -$147,826,724.